Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Therapy With FEC Followed by Weekly Paclitaxel and Concurrent Trastuzumab in Her2 Positive Non Operable Breast Cancer. Phase II Study.

NCT01340430 is registered in ClinicalTrials.gov with Lucia Del Mastro,MD as lead sponsor.

NCT NCT01340430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01340430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Therapy With FEC Followed by Weekly Paclitaxel and Concurrent Trastuzumab in Her2 Positive Non Operable Breast Cancer. Phase II Study.
Lead sponsor
Lucia Del Mastro,MD
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2011
Completion date
January 31, 2022
Enrollment
43 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

her-2 positive breast cancer